Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology

Reuters

05/20

Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology

Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536651074"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536651074\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536651074?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536651074","market":"nz","top_or_hot":-1,"title":"Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValue Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-20 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00806","symbol_name":"惠理集团","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL2hCrN6:1","article_id":"2536651074","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536651074","pubTimestamp":1747703000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00806":"惠理集团","BK1156":"资产管理与托管银行"},"translate_title":"惠理集团领投Phase Scientific 3400万美元A轮投资，推进尿液诊断技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00806":0.9},"content_text":"Value Partners Group Leads $34 Million Series A Investment in PHASE Scientific to Advance Urine-Based Diagnostic Technology\n    \n\n        Value Partners Group Limited has led a significant equity investment in PHASE Scientific International Limited, resulting in a US$34 million Series A funding round. This marks the largest Series A raise in Asia's diagnostic technology sector since 2019. The investment aims to accelerate the research and development and commercialization of PHASE Scientific's innovative urine-based diagnostic technology, which targets early detection of multiple cancers, women's health issues, and infectious diseases. Dr. Chuen Yan Leung, Partner at Value Partners Group, expressed confidence in PHASE Scientific's breakthrough technology and its potential to transform early disease detection.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Value Partners Group Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: HK90860) on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}